Maxzide

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxzide

Maxzide: What is This Combination Medicine?

Property Description
Active Ingredients Triamterene, Hydrochlorothiazide
Form Tablet or Capsule
Pharmacological Class Diuretic Combination, Antihypertensive Agent
General Purpose Fluid and Blood Pressure Management
Origin Synthetic

What Type of Medicine is Maxzide?

Maxzide is a trade name for a fixed-dose combination product, classified as an antihypertensive agent and a specialized diuretic combination medicine. This prescription-only (Rx) product is administered via the oral route, typically provided as a tablet or capsule. The two primary components, Triamterene and Hydrochlorothiazide, are both synthetic chemical compounds. This combination is clinically recognized for its role in managing conditions related to fluid retention and elevated pressure within the circulatory system.

Composition and Form: What is Maxzide Made Of?

The medicine incorporates the International Nonproprietary Names (INN) Triamterene and Hydrochlorothiazide. Hydrochlorothiazide is a thiazide diuretic that strongly promotes the excretion of sodium and water by the kidneys. Crucially, the formulation includes Triamterene, a potassium-sparing diuretic. This distinct inclusion is a defining characteristic, as it helps counteract the common side effect of potassium loss associated with single-agent thiazide diuretics, thereby helping to ensure potassium balance maintenance.

Maxzide's General Purpose and High-Level Action

The overarching purpose of Maxzide is to promote the increased salt and water removal from the body to manage fluid volume and pressure within the blood vessels. This dual action is achieved through the potent natriuresis facilitated by the thiazide component and the simultaneous potassium conservation ensured by Triamterene. A typical, neutral use scenario involves the medicine being prescribed to help regulate blood pressure in adult patients. By effectively reducing the amount of fluid circulating and minimizing critical electrolyte loss, the combination medicine provides the general benefit of supporting stable circulatory function.

Regulatory References

  1. NIH DailyMed Label

What side effects are possible with Maxzide?

Maxzide: Possible Side Effects and Safety Information

The official safety profile for the Triamterene / Hydrochlorothiazide combination is defined by expected effects primarily related to its diuretic action and Metabolism and Nutrition Disorders. These reactions are formally classified into System-Organ Classes in regulatory documents.


Documented Adverse Reactions

The most commonly listed adverse reactions include headache, dizziness, and Gastrointestinal Disorders such as nausea, vomiting, and dry mouth. Skin and Subcutaneous Tissue Disorders like rash and photosensitivity are also documented.


Critical Safety Concerns and Restrictions

Electrolyte Balance: A core safety feature of this combination is the opposing risks of Hyperkalemia (high potassium) due to Triamterene and Hypokalemia (low potassium) due to Hydrochlorothiazide. These electrolyte shifts are a primary focus of regulatory safety assessment.

Serious Reactions: Regulatory labeling documents rare but serious adverse reactions, including Acute Renal Failure, Hepatic Encephalopathy (in patients with liver disease), and Blood and Lymphatic System Disorders such as Agranulocytosis.

Safety Constraints: The medicine is formally contraindicated in patients with Anuria (lack of urine output), pre-existing Hyperkalemia, or Hypersensitivity to the drug or Sulfonamide-Derived Drugs. Safety has not been established for Pediatric Patients, and caution is mandated for patients with Severe Renal or Hepatic Disease.


Contextual Note: Orthostatic Hypotension (dizziness upon standing) is a documented vascular effect that may be aggravated by hot weather, and Electrolyte Imbalance may be associated with Prolonged Therapy.

Overdose and Emergency Response

Overdose and Immediate Medical Attention

Overdosage of Maxzide (triamterene and hydrochlorothiazide) is primarily characterized by the effects of overdiuresis (excessive water loss) and severe electrolyte disturbances in the body.

Immediate medical help is required if overdosage or severe symptoms occur. Overdose is considered a medical emergency, and the priority is to discontinue the medication and treat symptoms with supportive care to restore fluid and electrolyte balance.

Documented Overdose Symptoms Critical Electrolyte/Physiological Risks
Neurological/Systemic: Drowsiness, mental confusion, weakness, lethargy, fever. Hyperkalemia (high potassium) - potentially fatal risk, especially in patients with severe renal impairment, diabetes, or severe illness.
Cardiovascular: Hypotension (low blood pressure), tachycardia (rapid heart rate). Hypokalemia (low potassium), Hyponatremia (low sodium), Hypochloremia, Hypomagnesemia.
Gastrointestinal: Nausea, vomiting, dry mouth, excessive thirst. Overdiuresis and profound dehydration, metabolic acidosis.

In rare cases, severe electrolyte imbalance can precipitate a serious consequence such as hepatic coma in patients with cirrhosis. Life-threatening hyperkalemia is a primary concern for high-risk patients following an overdose. Treatment for overdose is supportive, focusing on correcting these critical fluid and electrolyte imbalances.

Therapeutic Uses of Maxzide

Maxzide is a fixed-dose combination medication that is applied across domains where additional symptomatic support is needed. It is commonly used for conditions presenting with acute episodes, specifically to manage high blood pressure (hypertension) and edema (fluid retention or swelling). Its application is relevant for easing symptoms related to physical discomfort and systemic imbalance in clinical settings that involve acute or unstable symptom patterns.

This combination of diuretics is generally applied when supportive symptom management is appropriate, especially where a lower risk of developing hypokalemia may be considered relevant. The potassium-sparing aspect assists with maintaining functional stability.

“This pairing assists with maintaining functional stability and contributes to easing the overall symptom load in conditions involving episodic or fluctuating manifestations.”

Relevant clinical contexts involve management of hypertension and symptoms associated with fluid retention.

Quick Fact: Relevant for Symptoms related to systemic imbalance

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Maxzide is a prescription-only medicine established for use in adult patients with hypertension or edema. It is specifically indicated for those who develop, or are at risk of developing, hypokalemia (low potassium) when taking hydrochlorothiazide alone.


Populations for Whom Use is Contraindicated

Use of Maxzide is strictly prohibited in patients with the following conditions, as stated in regulatory labeling:

  • Hyperkalemia (elevated serum potassium levels, ge 5.5 mEq/liter).
  • Anuria, acute and chronic renal insufficiency, or significant renal impairment.
  • Concurrent use of potassium-sparing agents (such as spironolactone or amiloride) or potassium supplements.
  • Known hypersensitivity to triamterene, hydrochlorothiazide, or other sulfonamide-derived drugs.

Age- and Condition-Based Eligibility

Safety and efficacy have not been established for the pediatric population. Geriatric patients require caution due to a heightened risk of hyperkalemia and kidney problems. For women, routine use during pregnancy is inappropriate, and breastfeeding is generally not recommended as the components pass into breast milk. Caution is also required in patients with severe hepatic impairment, Diabetes Mellitus, gout, or active Systemic Lupus Erythematosus (SLE).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific substance restrictions and pharmacokinetic patterns for Maxzide (Triamterene/Hydrochlorothiazide).

Contraindicated Combinations

Co-administration is formally prohibited with other potassium-conserving agents, such as spironolactone or amiloride hydrochloride. The use of potassium supplementation, including potassium-containing salt substitutes or potassium-enriched diets, is also strictly prohibited due to the risk of hyperkalemia. Use is further restricted in patients with elevated serum potassium levels (ge 5.5 mEq/liter).

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Documented Regulatory Outcome
Lithium Reduced renal clearance, leading to high risk of lithium toxicity.
NSAIDs (e.g., Indomethacin) Can reduce the diuretic and antihypertensive effects.
ACE Inhibitors / ARBs Greatly increased risk of hyperkalemia (additive effect).
Cholestyramine/Colestipol Impair the absorption of hydrochlorothiazide. Timing separation is required: administer at least two hours apart.
Alcohol / Narcotics May cause potentiation of orthostatic hypotension.

Population-Specific Interaction Notes

Elderly patients are noted in official labeling as being more susceptible to hyperkalemia. Diabetic patients may require dosage adjustments for antidiabetic agents due to the risk of hyperglycemia. Caution is advised for patients with impaired hepatic function, as minor fluid balance changes may precipitate hepatic coma.

Mechanism of Action

How Maxzide Works

Maxzide is a combination diuretic that modulates renal function by targeting two distinct sites within the nephron. The mechanism involves the combined action of the thiazide diuretic hydrochlorothiazide and the potassium-sparing diuretic triamterene.

Hydrochlorothiazide acts primarily on the distal convoluted tubule by inhibiting the sodium-chloride cotransporter (Na^+/Cl^-). Blocking this transporter reduces the passive reabsorption of sodium and chloride ions, resulting in decreased water reabsorption. Triamterene exerts its action in the collecting duct by functioning as a direct inhibitor of the epithelial sodium channel (ENaC). This blockade reduces sodium reabsorption at this site and attenuates potassium and hydrogen ion secretion.

The synergistic activity of these agents modulates electrolyte and water transport, promoting a combined increase in water and sodium excretion (diuresis) while minimizing potassium loss.

Dosage and Administration Information

How to use Maxzide: Official Administration Guidelines


Administration Scope

Route of administration: The fixed-dose combination medicine is administered via the oral route, typically provided as a tablet or capsule.

Dosing schedule: The maximum daily dosage limits are strictly defined. For the Maxzide 75 mg/50 mg strength, the usual dose is one tablet daily. For the lower-strength Maxzide-25 MG (37.5 mg/25 mg), the usual dose is one or two tablets daily. The total dose administered must not exceed one 75 mg/50 mg tablet or two 37.5 mg/25 mg tablets.

Timing in relation to meals (if applicable): Administration is generally permitted with or without food. Due to its expected diuretic effect, the single daily dose is typically advised to be taken in the morning.

Preparation requirements (if applicable): The medication is generally intended to be swallowed whole.

Age-group administration rules: Official guidelines indicate that safety and effectiveness have not been established in pediatric patients. Use of this medication is contraindicated in patients with anuria or significant renal impairment.

Missed-dose rules: If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped, and patients are instructed not to take a double dose.

Special procedural conditions: The fixed-combination product is not indicated for the initial therapy of hypertension or edema, except for individuals in whom the risk of hypokalemia is a specific clinical concern.


Instruction Classifications (High-Level)

Administration method type: Oral.

Frequency pattern: Once daily (qDay), administered as a single dose.

Basis for dosing regimens: Product labeling.

Use-context constraints: Not indicated for initial therapy and prohibited in the context of significant renal impairment.


Resulting procedural structure

Official step sequence:

  • Take the fixed-dose combination orally once per day, preferably in the morning.
  • Adhere strictly to the labeled strength and do not exceed the maximum daily dose as defined by the product labeling.
  • If a dose is missed, the dose is skipped if it is near the time of the next dose; double doses are forbidden.

Connection to the overall use protocol (2–4 sentences): The official usage protocol standardizes the administration of Maxzide to a once-daily oral regimen, with clearly defined maximum dose limits for adults. This guidance dictates that the medicine is reserved primarily for maintenance therapy or specific patient transfer scenarios, establishing clear limits by prohibiting its use in contexts of significant kidney impairment and lacking authorization for pediatric use.

Recent Clinical Evidence

Maxzide: Recent Clinical Evidence

Maxzide, a fixed-dose combination of the diuretic agents hydrochlorothiazide (HCTZ) and triamterene, is indicated for managing hypertension (high blood pressure) and edema (fluid retention). The combination is often used in patients who develop or are at risk of developing hypokalemia (low potassium levels) when taking HCTZ alone.


Research on Efficacy and Compound Profile

Studies have investigated the individual contributions of the two components to the overall therapeutic profile. HCTZ works in the kidney's distal convoluted tubules to promote the excretion of sodium and water. Triamterene, a potassium-sparing diuretic, acts on the distal renal tubule to inhibit sodium reabsorption and decrease potassium loss, countering the potassium-wasting effect of HCTZ.

  • Blood Pressure Reduction: Clinical trials have explored the combination's effect on blood pressure. One observational study noted that the combination therapy was associated with slightly lower systolic and diastolic blood pressure compared to HCTZ monotherapy, suggesting a potential contribution of triamterene to the blood pressure-lowering effect.
  • Electrolyte Balance: A primary focus of the combination's research is its potential to mitigate the risk of hypokalemia often observed with thiazide diuretics. Studies monitor the balance of electrolytes, especially potassium, to confirm the compensatory effect of triamterene.

Bioavailability and Safety Monitoring

Research conducted on the Maxzide tablet formulation focused on the bioavailability of its components, establishing that the active ingredients were absorbed to an extent comparable to liquid preparations given alone or in combination. This supports the clinical use of the fixed-dose tablet.

Mandatory Monitoring Endpoints:

Area of Focus Clinical Endpoints Monitored
Renal Function Serum creatinine and Blood Urea Nitrogen (BUN) levels.
Electrolyte Status Serum potassium, sodium, and chloride levels.
Metabolic Health Uric acid and glucose levels.

Ongoing clinical use and surveillance emphasize the importance of monitoring serum potassium levels due to the risk of hyperkalemia (high potassium) in specific populations, such as those with renal impairment or diabetes. Studies support the need for regular laboratory testing during therapy.

Frequently Asked Questions (FAQ)

Common questions about Maxzide (FAQ)


Q: Are headaches a common side effect when first starting Maxzide?

Regulatory documents state that headache is a commonly reported adverse reaction for this medication. However, official product information does not specifically indicate if this effect occurs more frequently only during the initial period of therapy.


Q: Is the risk of having too much potassium (hyperkalemia) common with Maxzide?

Official labeling warns that hyperkalemia (high potassium levels) is a serious risk, particularly for individuals with kidney problems or diabetes. Post-marketing surveillance data suggests the frequency is low in the general population, but it is important that patients undergo close monitoring by a healthcare professional, as described in official documents, due to the potential severity of this condition.


Q: Can Maxzide cause a dry mouth or increased thirst?

Dry mouth is listed as a common side effect of the medicine. Official warnings also note that increased thirst may occur, as it can be a sign of dehydration or an imbalance in the body's minerals (electrolytes), which are possible serious effects of diuretic therapy.


Q: How does Maxzide differ from other diuretics (water pills) like Lasix (furosemide)?

Maxzide is a combination of two types of water pills: a thiazide diuretic and a potassium-sparing diuretic. The component drugs work in the distal sections of the kidney's tubules. In contrast, Furosemide (Lasix) is a type of diuretic that acts on the Loop of Henle and has a mechanism of action that differs from Maxzide's components.


Q: What is the expected onset of the diuretic (peeing) effect after taking Maxzide?

According to official product information, the diuretic effect—meaning the increase in urination—typically begins a couple of hours after the dose is taken. This effect usually lasts for 6 to 12 hours. Official administration guidelines generally advise the medicine is taken in the morning to align with this duration of effect.


Q: Is Maxzide intended to be a long-term treatment for high blood pressure?

For the management of high blood pressure, this medication is generally intended to be taken regularly and continuously as part of a treatment plan. Patients are generally advised to continue taking the medication even if they begin to feel well, as blood pressure management is a long-term goal.


Q: Is it normal to feel more tired or weak when starting Maxzide therapy?

Tiredness is listed as a common adverse reaction in official safety documents. However, unusual tiredness or weakness that is severe or persistent may also indicate a serious issue such as low potassium (hypokalemia) or dehydration, which is why official guidance emphasizes the importance of monitoring.


Q: Does Maxzide cause weight loss, and is that fluid or actual body weight?

The medicine is indicated for treating edema (excess fluid retention), and its primary action is to increase the removal of salt and water from the body. Any resulting weight decrease is generally attributed to this fluid loss. Official labeling focuses on the medication's effect on fluid volume rather than classifying weight loss as a specific side effect.


Q: What signs of electrolyte imbalance should a patient watch for while taking Maxzide?

Signs of a potentially serious imbalance of minerals (electrolytes) or dehydration may include muscle cramps, muscle weakness, confusion, unusual dry mouth or thirst, nausea/vomiting, or a fast or irregular heartbeat. These signs are noted in regulatory documents as conditions that warrant immediate medical evaluation.


Q: Does Maxzide increase the risk of developing kidney stones?

Official safety data lists the formation of kidney stones as a possible, though unlikely, serious adverse effect that has been reported with this combination medication. This information is included in the warnings and side effects sections of regulatory documents.


Q: Is there a link between taking Maxzide and an increased risk of skin cancer?

Official documents state that the medication component, hydrochlorothiazide, is associated with photosensitivity (increased skin sensitivity to sunlight) and may increase the risk of certain types of skin cancer with long-term use. Official labeling notes that patients should limit sun exposure and use protective clothing.


Q: Can Maxzide cause vision changes or eye pain?

Blurred vision is a listed side effect of the medicine. Regulatory labeling includes a warning that a sudden decrease in vision or eye pain are rare but serious potential side effects that warrant prompt medical evaluation, according to official warnings.


Q: Is there any research evidence on the effectiveness of Maxzide for treating heart failure?

The fixed-dose combination product is formally indicated for the management of hypertension and general edema (fluid retention). One of the active ingredients, hydrochlorothiazide, is indicated by itself for the treatment of fluid retention associated with conditions including congestive heart failure.


Q: Does Maxzide affect sexual function or cause changes in libido?

Official safety reports indicate that decreased sexual ability or loss of libido (sexual desire or drive) have been reported as rare side effects in patients using this combination medication.


Q: Is it necessary to be on a special low-salt diet while taking Maxzide?

Regulatory information for the medication's components advises that the management of high blood pressure often includes lifestyle changes, such as following a low-sodium meal plan (low-salt diet). Following such a plan is typically recommended to maximize the blood pressure-lowering effect of the medicine.


Q: What is the difference between Maxzide and Dyazide?

Maxzide and Dyazide are both brand names for a fixed-dose combination of the same active ingredients: triamterene and hydrochlorothiazide. They may be available in different forms or strengths; for instance, Maxzide is available as a tablet or capsule, while Dyazide is available as a capsule.


Q: Is Maxzide known to cause muscle cramps or muscle weakness?

Muscle cramps and muscle weakness are listed in official safety documents as possible signs of fluid or mineral loss, which are potentially serious side effects of diuretic therapy. According to official documentation, these symptoms are conditions that warrant evaluation by a healthcare professional.


Q: What happens if a patient stops taking Maxzide suddenly?

Sudden discontinuation of an antihypertensive medicine like Maxzide may cause a rapid increase in blood pressure to the level it was before treatment, or possibly higher. Official documentation notes that this type of medication should generally not be stopped abruptly without the guidance of a healthcare professional.

How should Maxzide be stored and disposed of?

How to Store and Dispose of Maxzide?

Maxzide (triamterene and hydrochlorothiazide) storage and disposal must strictly adhere to regulatory guidelines to ensure product stability and safety.

Official Storage Requirements

Requirement Rule based on Regulatory Labeling
Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).
Environment Keep the medicine from freezing and store away from excess heat, moisture, and direct light.
Container Maintain in the original container, and keep it tightly closed.
Safety Store out of the sight and reach of children and pets, using locked safety caps.

Disposal Instructions

Expired or unused Maxzide must be discarded according to official procedures. The recommended method is to use a drug take-back program or mail-back envelope. If no take-back option is available, the product may be disposed of in household trash by mixing it with an unappealing substance, sealing it in a container, and then discarding it. Do not flush this medication down the toilet or pour it down a drain, as it is not on the government's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxzide found in:

A-Z Index: